Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Oral azacytidine for low-risk MDS - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Oral azacytidine for low-risk MDS

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Oral azacytidine for low-risk MDS

New Indication: Oral azacytidine for low-risk MDS
Study:
  • Placebo-controlled phase III trial
  • IPSS-defined low-risk MDS with anemia and thrombocytopenia
  • Oral azacytidine 300 mg (21/28 days) vs. placebo
Efficacy:
  • RBC-Transfusion independence (TI) >56 days: 30.8% vs. 11.1% (OR: 3.6 [1.7-7.4])
  • Median duration for RBC-TI: 11.1 vs 5.0 mos (NS)
  • Hematological improvement in RBCs: 43.0% vs. 31.5% (NS)
  • Median OS: 17.3 vs. 16.2 mos (NS)
Safety:
  • Grade >=3 AEs: neutropenia (47% vs. 12%), febrile neutropenia (28% vs. 10%), thrombocytopenia (29% vs. 16%), pneumonia (12% vs. 9%)

J Clin Oncol. Mar 25, 2021.

Garcia-Manero G, et al. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

https://doi.org/10.1200/JCO.20.02619

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More